These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 11745247)

  • 21. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
    Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
    Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
    Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
    Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience of capecitabine in metastatic breast cancer.
    O'Shaughnessy J
    Eur J Cancer; 2002 Feb; 38 Suppl 2():10-4. PubMed ID: 11841930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
    Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
    Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
    Tagaya N; Nakagawa A; Mori S; Tachibana M; Kakihara Y; Hamada K; Suzuki N; Kubota K
    Gan To Kagaku Ryoho; 2005 Aug; 32(8):1135-8. PubMed ID: 16121915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study.
    Gradishar WJ; Meza LA; Amin B; Samid D; Hill T; Chen YM; Lower EE; Marcom PK
    J Clin Oncol; 2004 Jun; 22(12):2321-7. PubMed ID: 15197193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
    Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
    Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study.
    Jakob A; Bokemeyer C; Knop S; Schupp M; Mayer F; Kanz L
    Anticancer Drugs; 2002 Apr; 13(4):405-10. PubMed ID: 11984086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
    Wist EA; Sommer HH; Ostenstad B; Risberg T; Bremnes Y; Mjaaland I
    Acta Oncol; 2004; 43(2):186-9. PubMed ID: 15163168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Xeloda in the treatment of metastatic breast cancer.
    Blum JL
    Oncology; 1999 Jul; 57 Suppl 1():16-20. PubMed ID: 10436412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
    Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
    Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
    Yamamoto D; Iwase S; Yoshida H; Kuroda Y; Yamamoto C; Kitamura K; Odagiri H; Nagumo Y
    Anticancer Res; 2010 Sep; 30(9):3827-31. PubMed ID: 20944178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
    Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
    Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.